Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial-Reference-Cited by-同舟云学术

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

Published:2017-05 Issue:5 Volume:18 Page:623-630
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Alley Evan W,Lopez Juanita,Santoro Armando,Morosky Anne,Saraf Sanatan,Piperdi Bilal,van Brummelen Emilie

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Malignant pleural mesothelioma: an epidemiological perspective;Robinson;Ann Cardiothorac Surg,2012

2. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma;Goudar;Ther Clin Risk Manag,2008

3. Pathology of mesothelioma;Inai;Environ Health Prev Med,2008

4. Malignant pleural mesothelioma: a population-based study of survival;Milano;J Thorac Oncol,2010

Cited by 418 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human TCR repertoire in cancer;Cancer Medicine;2024-09

2. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma;Lung Cancer;2024-09

3. Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies;Biomarkers in Medicine;2024-08-15

4. Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis;Investigational New Drugs;2024-08-14

5. Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma;Heliyon;2024-08